Raymond James & Associates’s Pfizer PFE Stock Holding History

Raymond James & Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-400	Closed	-$16K	–	3901
2023 Q2	$16K	Hold	400	–	–	﹤0.01%	3785
2023 Q1	$16K	Sell	400 -29,400	-99%	-$1.27M	﹤0.01%	3810
2022 Q4	$209K	Sell	29,800 -1,200	-4%	-$57.5K	﹤0.01%	3430
2022 Q3	$61K	Buy	31,000 +4,600	+17%	+$224K	﹤0.01%	3685
2022 Q2	$239K	Sell	26,400 -45,400	-63%	-$2.31M	﹤0.01%	3388
2022 Q1	$678K	Sell	71,800 -15,200	-17%	-$789K	﹤0.01%	2875
2021 Q4	$1.24M	Sell	87,000 -19,800	-19%	-$981K	﹤0.01%	2479
2021 Q3	$266K	Sell	106,800 -39,400	-27%	-$1.75M	﹤0.01%	3499
2021 Q2	$89K	Buy	146,200 +34,500	+31%	+$1.34M	﹤0.01%	3856
2021 Q1	$54K	Buy	111,700 +29,600	+36%	+$1.05M	﹤0.01%	3848
2020 Q4	$17K	Buy	82,100 +27,608	+51%	+$1.01M	﹤0.01%	3700
2020 Q3	$28K	Buy	54,492 +15,916	+41%	+$558K	﹤0.01%	3491
2020 Q2	$9K	Sell	38,576 -189,615	-83%	-$6.44M	﹤0.01%	3486
2020 Q1	$56K	Buy	228,191 +14,967	+7%	+$510K	﹤0.01%	3303
2019 Q4	$40K	Buy	213,224 +5,270	+3%	+$188K	﹤0.01%	3569
2019 Q3	$18K	Sell	207,954 -139,761	-40%	-$5.08M	﹤0.01%	3542
2019 Q2	$204K	Buy	347,715 +113,305	+48%	+$4.5M	﹤0.01%	3249
2019 Q1	$38K	Buy	234,410 +85,796	+58%	+$3.44M	﹤0.01%	3495
2018 Q4	$183K	Sell	148,614 -185,715	-56%	-$7.71M	﹤0.01%	3167
2018 Q3	$878K	Buy	334,329 +96,125	+40%	+$3.7M	﹤0.01%	2333
2018 Q2	$126K	Sell	238,204 -29,301	-11%	-$1M	﹤0.01%	3365
2018 Q1	$164K	Sell	267,505 -100,763	-27%	-$3.46M	﹤0.01%	3193
2017 Q4	$209K	Sell	368,268 -42,792	-10%	-$1.46M	﹤0.01%	3035
2017 Q3	$310K	Buy	411,060 +78,734	+24%	+$2.53M	﹤0.01%	2772
2017 Q2	$63K	Sell	332,326 -35,836	-10%	-$1.13M	﹤0.01%	3166
2017 Q1	$88K	Buy	368,162 +126,480	+52%	+$3.99M	﹤0.01%	3084
2016 Q4	$33K	Sell	241,682 -97,284	-29%	-$2.97M	﹤0.01%	3122
2016 Q3	$42K	Buy	338,966 +161,999	+92%	+$5.42M	﹤0.01%	3090
2016 Q2	$148K	Buy	176,967 +70,618	+66%	+$2.25M	﹤0.01%	2737
2016 Q1	$7K	Buy	+106,349	New	+$3.04M	﹤0.01%	2899

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Raymond James & Associates's PFE Position: Q3 2024 in Review

Raymond James & Associates reduced its Pfizer (PFE) stake by 4.1% in Q3 2024, selling an estimated $10.2M and leaving 8,209,415 shares worth $238M. The position accounts for 0.14% of the portfolio, ranked #123.

Raymond James & Associates first reported a position in PFE in Q2 2013 and has held it in 46 quarters since. The position peaked at $564M in Q4 2019. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.

Raymond James & Associates held 8,209,415 shares of Pfizer worth $238M as of Q3 2024.
Raymond James & Associates sold 349,305 Pfizer shares in Q3 2024, an estimated $10.2M.
Pfizer made up 0.14% of Raymond James & Associates's portfolio in Q3 2024, its #123 holding.
Raymond James & Associates first reported a position in Pfizer in Q2 2013 and has held it in 46 quarters since.
Raymond James & Associates's Pfizer position peaked at $564M in Q4 2019.
2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.